Skull base neoplasm

Summary

Skull base neoplasm (MONDO:0002785) is a cancer (an umbrella term covering 5 Mondo subtypes) and 19 clinical trials. Top therapeutic interventions include indocyanine green acid form, aminolevulinic acid hydrochloride, and toripalimab. A subtype of skull neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Umbrella term: 5 Mondo subtypes
• Clinical trials: 19

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	skull base neoplasm
Mondo ID	MONDO:0002785
MeSH	D019292
DOID	DOID:3842
NCIT	C4676
UMLS	C0376527
MedGen	138208
GARD	0023244
Anatomy (UBERON)	UBERON:0002517
Is cancer (heuristic)	yes

Also known as: basicranium neoplasm · basicranium neoplasm (disease) · basicranium tumor · basicranium tumour · neoplasm of basicranium · neoplasm of skull base · neoplasm of the skull base · skull base neoplasm · skull base tumor · skull base tumour · tumor of basicranium · tumor of skull base · tumor of the skull base · tumour of basicranium · tumour of skull base · tumour of the skull base · tumours of skull base

Disease family

An umbrella term covering 5 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › head and neck neoplasm › skull neoplasm › skull base neoplasm

Related subtypes (6): skull cancer, jugular foramen meningioma, schwannoma of jugular foramen, paranasal sinus neoplasm, neoplasm of jaw, orbit neoplasm

Subtypes (5): sella turcica neoplasm, skull base chordoma, skull base meningioma, sphenoidal sinus neoplasm, jugulotympanic paraganglioma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 19.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	17
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07209189	PHASE2	RECRUITING	Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)
NCT05101798	PHASE2	TERMINATED	The Role of 5-Aminolevulinic Acid Fluorescence-Guided Surgery in Head and Neck Cancers: a Pilot Trial
NCT03759717	Not specified	RECRUITING	Molecular and Cellular Characterization of Skull Base Tumors
NCT03972514	Not specified	ACTIVE_NOT_RECRUITING	Observational Trial of the Impact of Radiation Dose in Children With Brain and Skull Base Tumors.
NCT05607888	Not specified	RECRUITING	Prospective Study of Sinonasal and Skull-base Tumours Management
NCT05898074	Not specified	RECRUITING	Role of Novel RADA16 Hydrogel in Endoscopic Skull Base Surgery
NCT06495580	Not specified	NOT_YET_RECRUITING	Optic Nerve Stimulation To Prevent Visual Deficits After Endoscopic Cranial Approaches
NCT06501716	Not specified	NOT_YET_RECRUITING	ICG Angiogram as a Predictor of Postoperative Visual Function After EEA Surgery
NCT06587906	Not specified	RECRUITING	Postoperative Complications Following Skull Base Tumor Resection
NCT06724029	Not specified	RECRUITING	Neurosurgical Outcome Network
NCT01228448	Not specified	COMPLETED	In-Room PET in Proton Radiation Therapy
NCT02117310	Not specified	COMPLETED	ICG Use in Angiography for Nasoseptal Flap Harvest
NCT02988804	Not specified	COMPLETED	Effects on the Awakening With Laryngeal Mask vs Endotracheal Tube in Endoscopic Endonasal Transsphenoidal Base Surgery
NCT03072186	Not specified	COMPLETED	Proposal for Intraoperative Administration of Intravenous Indocyanine Green to Evaluate Position of the Optic Canal, Position of the Internal Carotid Arteries, Tumor Vascularization, and Vessel Encasement in Endoscopic Endonasal Cranial Base Surgery
NCT03448614	Not specified	UNKNOWN	Skull Base Reconstruction After Endonasal Cranio-endoscopic Resection Using Autologus Grafts
NCT04241679	Not specified	COMPLETED	Auditory Nerve Test System During Vestibular Schwannoma Resection
NCT04249921	Not specified	UNKNOWN	Evaluation of Acupuncture Effects for Complications After Surgery of Cerebellopontine Angle Tumor in Skull Base
NCT04374448	Not specified	UNKNOWN	Utility of Indocyanine Green Fluorescence in Endoscopic Sinonasal and Skull Base Surgery
NCT05912881	Not specified	COMPLETED	Chemosensory Dysfunction and Recovery in Endoscopic Endonasal Skull Base Surgery

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
INDOCYANINE GREEN ACID FORM	4	2
AMINOLEVULINIC ACID HYDROCHLORIDE	4	1
TORIPALIMAB	4	1